Yervoy

Adult Dosing .

Dosage forms:  INJ

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

melanoma

[adjuvant tx]

Dose: 3 mg/kg/dose IV q3wk for max 4 doses, then 3 mg/kg/dose IV q12wk for up to 4 doses; Info: for cutaneous disease with regional lymph nodes involvement that have undergone complete resection

[unresectable or metastatic disease]

Dose: 3 mg/kg/dose IV q3wk x4 doses; Max: 4 doses; Info: complete tx within 16wk after 1st dose; use as monotherapy or with nivolumab

renal cell CA, advanced

[1 mg/kg/dose IV q3wk x4 doses]

Max: 4 doses; Info: for patients with previously untreated intermediate or poor risk disease; first-line tx; use with nivolumab

microsatellite instability-high or mismatch repair deficient colorectal CA, unresectable or metastatic

[1 mg/kg/dose IV q3wk x4 doses]

Max: 4 doses; Info: use with nivolumab

hepatocellular CA

[3 mg/kg/dose IV q3wk for up to 4 doses]

Info: for sorafenib refractory or intolerant disease; use with nivolumab

non-small cell lung CA

[PD-L1-expressing metastatic disease]

Dose: 1 mg/kg/dose IV q6wk for up to 2y; Info: for patients with no EGFR or ALK genomic tumor aberrations; first-line tx; use with nivolumab

[metastatic or recurrent disease]

Dose: 1 mg/kg/dose IV q6wk for up to 2y; Info: for patients with no EGFR or ALK genomic tumor aberrations; first-line tx; use with nivolumab and 2 cycles of q3wk histology-based platinum-doublet chemo

malignant pleural mesothelioma, unresectable

[1 mg/kg/dose IV q6wk for up to 2y]

Info: first-line tx; use with nivolumab

esophageal CA

[1 mg/kg/dose IV q6wk for up to 2y]

Info: for patients with PD-L1-expressing unresectable advanced or metastatic esophageal squamous cell carcinoma; first-line tx; use with nivolumab

renal dosing

[see below]

CrCl >15: no adjustment; CrCl <15: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined

Peds Dosing .

Dosage forms:  INJ

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

melanoma, unresectable or metastatic

[12 yo and older]

Dose: 3 mg/kg/dose IV q3wk x4 doses; Max: 4 doses; Info: complete tx within 16wk after 1st dose; use as monotherapy or with nivolumab

microsatellite instability-high or mismatch repair deficient colorectal CA, unresectable or metastatic

[12 yo and older]

Dose: 1 mg/kg/dose IV q3wk x4 doses; Max: 4 doses; Info: use with nivolumab

renal dosing

[see below]

CrCl >15: no adjustment; CrCl <15: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined